A Phase 3, Open-label, Multicenter, Long-term Study to Evaluate the Safety and Efficacy of TAK-536, Amlodipine and Hydrochlorothiazide in Subjects With Essential Hypertension

Trial Profile

A Phase 3, Open-label, Multicenter, Long-term Study to Evaluate the Safety and Efficacy of TAK-536, Amlodipine and Hydrochlorothiazide in Subjects With Essential Hypertension

Completed
Phase of Trial: Phase III

Latest Information Update: 29 Jun 2017

At a glance

  • Drugs Amlodipine/azilsartan (Primary) ; Amlodipine/azilsartan/hydrochlorothiazide (Primary) ; Hydrochlorothiazide
  • Indications Essential hypertension
  • Focus Adverse reactions
  • Sponsors Takeda
  • Most Recent Events

    • 09 Jul 2016 Planned number of patients changed to 341.
    • 05 Jul 2016 Status changed from active, no longer recruiting to completed.
    • 15 Dec 2015 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top